<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2019-15-5-690-696</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PREVENTIVE CARDIOLOGY AND PUBLIC HEALTH</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОФИЛАКТИЧЕСКАЯ КАРДИОЛОГИЯ И ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ</subject></subj-group></article-categories><title-group><article-title>Comparative Study of the Results of a Three-year Observation of Cardiologists and Surgeons in Patients with Peripheral Atherosclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Сравнительное исследование результатов трехлетнего наблюдения у кардиологов и хирургов пациентов с облитерирующим атеросклерозом нижних конечностей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барбараш</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Barbarash</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН, главный научный сотрудник,</p><p>650002, Кемерово, Сосновый б-р, 6</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the Russian Academy of Sciences, Chief Researcher,</p><p>Sosnoviy bulv. 6, Kemerovo, 650002</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сумин</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sumin</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., зав. отделом мультифокального атеросклероза,</p><p>650002, Кемерово, Сосновый б-р, 6</p></bio><bio xml:lang="en"><p>MD, PhD, Head of Department of Multifocal Atherosclerosis,</p><p>Sosnoviy bulv. 6, Kemerovo, 650002</p></bio><email xlink:type="simple">an_sumin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медведева</surname><given-names>Ю. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvedeva</surname><given-names>Yu. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач, сердечно-сосудистый хирург,</p><p>650002, Кемерово, Сосновый б-р, 6</p></bio><bio xml:lang="en"><p>MD, Cardiovascular Surgeon,</p><p>Sosnoviy bulv. 6, Kemerovo, 650002 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корок</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korok</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., н.с., лаборатория патологии кровообращения отдела мультифокального атеросклероза, </p><p>650002, Кемерово, Сосновый б-р, 6</p></bio><bio xml:lang="en"><p>MD, PhD, Researcher, Laboratory of Circulatory Pathology, Department of Multifocal Atherosclerosis, </p><p>Sosnoviy bulv. 6, Kemerovo, 650002</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кемеровский областной клинический кардиологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kemerovo Regional Cardiology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>05</day><month>11</month><year>2019</year></pub-date><volume>15</volume><issue>5</issue><fpage>690</fpage><lpage>696</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Barbarash L.S., Sumin A.N., Medvedeva Y.D., Korok E.V., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Барбараш Л.С., Сумин А.Н., Медведева Ю.Д., Корок Е.В.</copyright-holder><copyright-holder xml:lang="en">Barbarash L.S., Sumin A.N., Medvedeva Y.D., Korok E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2040">https://www.rpcardio.online/jour/article/view/2040</self-uri><abstract><sec><title>Aim</title><p>Aim. To compare the results of 3-year follow-up of patients with peripheral atherosclerosis (PA) in two patient cohorts: during outpatient monitoring by cardiologists and when observed by surgeons.</p></sec><sec><title>Material and methods</title><p>Material and methods. The first group included 131 patients with PA who sought medical attention in outpatient clinic in 2013-2014 and then were observed by a surgeon. The second group is represented by 454 patients with PA who sought medical attention in outpatient clinic in 2010- 2012 and then underwent observation by a cardiologist as a part of a pilot project. The average follow-up duration in the studied groups was three years. The groups were compared according to the main demographic, anthropometric indicators, the presence of risk factors for atherosclerosis, comorbidity, the prevalence of atherothrombotic events in history, laboratory and instrumental examination data. Additionally, after 3 years of observation the incidence of deaths and amputations was assessed in groups.</p></sec><sec><title>Results</title><p>Results. Patients of the second group were older than these in the first group (p&lt;0.001). Patients of the group 1 compared to the group 2 were more often overweight (p=0.005), suffered from diabetes mellitus (p&lt;0.001), had a disability (p&lt;0.001). Among patients of the group 2 compared with the group 1, the clinical picture of angina pectoris (p=0.001), rhythm disorders (p=0.058) were more often observed, they had a greater number of myocardial infarctions (p&lt;0.001) and myocardial revascularization operations in the history: coronary bypass surgery (p=0.029), percutaneous coronary interventions (p&lt;0.001), and underwent coronary angiography (p&lt;0.001). Patients in group 2 were more likely to receive statins (p&lt;0.001), β-blockers (p&lt;0.001), angiotensin-converting enzyme inhibitors, and calcium channel blockers, angiotensin II receptor blockers, and antiarrhythmics (p&lt;0.001). Pentoxifylline was prescribed more often in the first group (p&lt;0.001). With a three-year observation of PA patients a fatal outcome occurred in 8.2% of cases, amputation – in 1.4%. In the first group, compared with the second one, there were more often observed deaths in general (p=0.023), death from cardiac causes, stroke, disability (p=0.005) and amputations (p=0.003). The risk of adverse outcomes (death and amputations) was increased in the presence of signs of chronic lower limb ischemia of stage III, a history of amputation, more than 70% stenosis and occlusions of lower limb arteries, chronic lung disease, and angina symptoms. The risk of adverse outcomes was decreased in outpatient observation by cardiologist, taking statins, aspirin, and performing exercise therapy.</p></sec><sec><title>Conclusion</title><p>Conclusion. Observation of PA patients by a cardiologist results in more frequent optimal drug therapy (due to the better adherence of cardiologists to clinical recommendations for the treatment of such patients) and improves the prognosis of these patients. </p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Сопоставить результаты 3-х-летнего наблюдения за больными облитерирующим атеросклерозом артерий нижних конечностей (ОЗАНК) в двух когортах больных: при амбулаторном наблюдении у кардиологов и при наблюдении хирургами поликлиники.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проведен анализ данных 585 пациентов, проходивших амбулаторное наблюдение по поводу ОЗАНК. В первую группу включены пациенты (n=131), обратившиеся с диагнозом ОЗАНК в поликлинику в 2013-2014 гг. и наблюдавшиеся затем у хирурга поликлиники. Вторая группа представлена 454 пациентами, обратившимся в поликлинику в 2010-2012 гг. и проходившими затем наблюдение у кардиолога в рамках пилотного проекта. Средний период наблюдения в исследуемых группах составил 3 года. Группы были сопоставлены по основным демографическим, антропометрическим показателям, наличию факторов риска атеросклероза, сопутствующей патологии, распространенности атеротромботических событий в анамнезе, данным лабораторного и инструментального обследования. Дополнительно через 3 года наблюдения в группах оценивали частоту летальных исходов и ампутаций.</p></sec><sec><title>Результаты</title><p>Результаты. Больные 2 группы были старше, чем в 1 группе (р&lt;0,001). Больные 1 группы по отношению ко 2 группе чаще имели избыточный вес (р=0,005), страдали сахарным диабетом (р&lt;0,001), имели инвалидность (р&lt;0,001). Среди пациентов 2 группы по сравнению с 1 группой чаще прослеживалась клиническая картина стенокардии (р=0,001), нарушения ритма (р=0,058), они имели большее количество инфарктов миокарда (р&lt;0,001) и операций реваскуляризации миокарда в анамнезе – коронарное шунтирование (р=0,029) и чрескожные коронарные вмешательства (р&lt;0,001), больным 2 группы чаще выполняли коронароангиографию (р&lt;0,001). Больным 2 группы чаще, чем в 1 группе назначали статины (87% и 63,4%, соответственно; р&lt;0,001), β-адреноблокаторы (80,4% и 32,8%, соответственно; р&lt;0,001), ингибиторы ангиотензинпревращающего фермента (иАПФ), блокаторы кальциевых каналов, блокаторы рецепторов ангиотензина II (БРА), антиаритмические препараты (р&lt;0,001). В то же время в 1-й группе чаще чем во 2-й группе назначали пентоксифиллин (62,6% и 23,1%, соответственно; р&lt;0,001). При трехлетнем наблюдении за больными ОЗАНК летальный исход произошел в 8,2% случаев, ампутации – в 1,4%. В 1-й группе по сравнению со 2-й чаще наблюдались летальные исходы в целом (13% и 6,8%, соответственно; р=0,023), смерть от кардиальных причин, инсульта, а также стойкая утрата трудоспособности (26,7% и 16,1%, соответственно; р=0,005) и ампутации (4,6% и 0,4%, соответственно; р=0,003). Увеличивали риск неблагоприятных исходов (летальный исход и ампутации) наличие признаков хронической ишемии нижних конечностей III стадии, ампутации в анамнезе, стенозов более 70% и окклюзий артерий нижних конечностей, хронических заболеваний легких, симптомов стенокардии. Улучшали прогноз пациентов диспансерное наблюдение у кардиолога, прием статинов, аспирина и проведение лечебной физкультуры.</p></sec><sec><title>Заключение</title><p>Заключение. Диспансерное наблюдение больных ОЗАНК у кардиолога вследствие лучшей приверженности врачей-кардиологов клиническим рекомендациям по лечению таких больных способствует большей частоте приема оптимальной медикаментозной терапии пациентами и, как следствие, способно улучшить прогноз этой группы пациентов. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>периферический атеросклероз</kwd><kwd>амбулаторное наблюдение</kwd><kwd>оптимальная медикаментозная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>peripheral atherosclerosis</kwd><kwd>outpatient monitoring</kwd><kwd>optimal medical therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hussain M.A., Al-Omran M., Mamdani M., et al. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. JAMA Surg. 2016;151(8):742-50. DOI:10.1001/jamasurg.2016.0415.</mixed-citation><mixed-citation xml:lang="en">Hussain M.A., Al-Omran M., Mamdani M., et al. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. JAMA Surg. 2016;151(8):742-50. DOI:10.1001/jamasurg.2016.0415.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Blinc A., Kozak M., Šabovič M., et al. Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease. Int Angiol. 2017;36(3):216-27. DOI:10.23736/S0392-9590.16.03731-7.</mixed-citation><mixed-citation xml:lang="en">Blinc A., Kozak M., Šabovič M., et al. Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease. Int Angiol. 2017;36(3):216-27. DOI:10.23736/S0392-9590.16.03731-7.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">O'Donnell T.F.X., Deery S.E., Darling J.D., et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2017;66(2):572-8. DOI:10.1016/j.jvs.2017.03.416.</mixed-citation><mixed-citation xml:lang="en">O'Donnell T.F.X., Deery S.E., Darling J.D., et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2017;66(2):572-8. DOI:10.1016/j.jvs.2017.03.416.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Thiney M., Della Schiava N., Ecochard R., et al. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization. Ann Vasc Surg. 2018;52:138-46. DOI:10.1016/j.avsg.2018.03.021.DOI:10.1161/JAHA. 117.005699.</mixed-citation><mixed-citation xml:lang="en">Thiney M., Della Schiava N., Ecochard R., et al. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization. Ann Vasc Surg. 2018;52:138-46. DOI:10.1016/j.avsg.2018.03.021.DOI:10.1161/JAHA. 117.005699.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Foley T.R., Singh G.D., Kokkinidis D.G., et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2017;6(7):e005699. DOI:10. 1161/JAHA.117.005699.</mixed-citation><mixed-citation xml:lang="en">Foley T.R., Singh G.D., Kokkinidis D.G., et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2017;6(7):e005699. DOI:10. 1161/JAHA.117.005699.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong E.J., Chen D.C., Westin G.G., et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. DOI:10.1161/JAHA.113.000697.</mixed-citation><mixed-citation xml:lang="en">Armstrong E.J., Chen D.C., Westin G.G., et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. DOI:10.1161/JAHA.113.000697.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chen D.C., Armstrong E.J., Singh G.D., et al. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag. 2015;11:185-92. DOI:10.2147/VHRM.S76651.</mixed-citation><mixed-citation xml:lang="en">Chen D.C., Armstrong E.J., Singh G.D., et al. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag. 2015;11:185-92. DOI:10.2147/VHRM.S76651.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Poredos P., Jezovnik M.K. Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease? Int J Mol Sci. 2015;16(7):14477-89. DOI:10.3390/ijms160714477.</mixed-citation><mixed-citation xml:lang="en">Poredos P., Jezovnik M.K. Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease? Int J Mol Sci. 2015;16(7):14477-89. DOI:10.3390/ijms160714477.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Berger J.S., Ladapo J.A. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2017;69(18):2293-300. DOI:10.1016/j.jacc.2017.02.064.</mixed-citation><mixed-citation xml:lang="en">Berger J.S., Ladapo J.A. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2017;69(18):2293-300. DOI:10.1016/j.jacc.2017.02.064.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McBride C.L., Akeroyd J.M., Ramsey D.J., et al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018;23(3):232-40. DOI:10.1177/1358863X18758914.</mixed-citation><mixed-citation xml:lang="en">McBride C.L., Akeroyd J.M., Ramsey D.J., et al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018;23(3):232-40. DOI:10.1177/1358863X18758914.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Renard B.M., Seth M., Share D., et al. If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease. Vasc Med. 2015;20(6):544-50. DOI:10.1177/1358863X15599249.</mixed-citation><mixed-citation xml:lang="en">Renard B.M., Seth M., Share D., et al. If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease. Vasc Med. 2015;20(6):544-50. DOI:10.1177/1358863X15599249.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Montminy M.L., Gauvin V., Turcotte S., et al. Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease. PLoS One. 2016;11(2):e0148069. DOI:10.1371/journal.pone.0148069.</mixed-citation><mixed-citation xml:lang="en">Montminy M.L., Gauvin V., Turcotte S., et al. Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease. PLoS One. 2016;11(2):e0148069. DOI:10.1371/journal.pone.0148069.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sigvant B., Kragsterman B., Falkenberg M., et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg. 2016;64(4):1009-17.e3. DOI:10.1016/j.jvs.2016.03.429.</mixed-citation><mixed-citation xml:lang="en">Sigvant B., Kragsterman B., Falkenberg M., et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg. 2016;64(4):1009-17.e3. DOI:10.1016/j.jvs.2016.03.429.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Thiney M., Della Schiava N., Feugier P., et al. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease. Ann Vasc Surg. 2017;40:85-93. DOI:10.1016/j.avsg.2016.08.030.</mixed-citation><mixed-citation xml:lang="en">Thiney M., Della Schiava N., Feugier P., et al. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease. Ann Vasc Surg. 2017;40:85-93. DOI:10.1016/j.avsg.2016.08.030.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Meltzer A.J., Sedrakyan A., Connolly P.H., et al.; Vascular Study Group of Greater. Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2018;46:234-40. DOI:10.1016/j.avsg.2017.05.030.</mixed-citation><mixed-citation xml:lang="en">Meltzer A.J., Sedrakyan A., Connolly P.H., et al.; Vascular Study Group of Greater. Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2018;46:234-40. DOI:10.1016/j.avsg.2017.05.030.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kumbhani D.J., Steg P.G., Cannon C.P., et al.; REACH Registry Investigators. Statin therapy and longterm adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. DOI:10.1093/eurheartj/ehu080.</mixed-citation><mixed-citation xml:lang="en">Kumbhani D.J., Steg P.G., Cannon C.P., et al.; REACH Registry Investigators. Statin therapy and longterm adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. DOI:10.1093/eurheartj/ehu080.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Arya S., Khakharia A., Binney Z.O., et al. Association of Statin Dose with Amputation and Survival in Patients With Peripheral Artery Disease. Circulation. 2018;137(14):1435-46. DOI:10.1161/CIRCULATIONAHA.117.032361.</mixed-citation><mixed-citation xml:lang="en">Arya S., Khakharia A., Binney Z.O., et al. Association of Statin Dose with Amputation and Survival in Patients With Peripheral Artery Disease. Circulation. 2018;137(14):1435-46. DOI:10.1161/CIRCULATIONAHA.117.032361.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bodewes T.C.F., Darling J.D., O'Donnell T.F.X., et al. Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention. J Vasc Surg. 2018;67(3):800-8.e1. DOI:10.1016/j.jvs.2017.07.130.</mixed-citation><mixed-citation xml:lang="en">Bodewes T.C.F., Darling J.D., O'Donnell T.F.X., et al. Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention. J Vasc Surg. 2018;67(3):800-8.e1. DOI:10.1016/j.jvs.2017.07.130.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Aboyans V., Ricco J.B., Bartelink M.E.L., et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. Eur Heart J. 2018;39(9):763-816. DOI:10.1093/eurheartj/ehx095.</mixed-citation><mixed-citation xml:lang="en">Aboyans V., Ricco J.B., Bartelink M.E.L., et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. Eur Heart J. 2018;39(9):763-816. DOI:10.1093/eurheartj/ehx095.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cea-Soriano L., Fowkes F.G.R., Johansson S., et al. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open. 2018;8(1):e018184. DOI:10.1136/bmjopen-2017-018184.</mixed-citation><mixed-citation xml:lang="en">Cea-Soriano L., Fowkes F.G.R., Johansson S., et al. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open. 2018;8(1):e018184. DOI:10.1136/bmjopen-2017-018184.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lane R., Harwood A., Watson L., Leng G.C. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017 Dec 26;12:CD000990. DOI:10.1002/14651858.CD000990.pub4.</mixed-citation><mixed-citation xml:lang="en">Lane R., Harwood A., Watson L., Leng G.C. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017 Dec 26;12:CD000990. DOI:10.1002/14651858.CD000990.pub4.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Devrome A.N., Aggarwal S., McMurtry M.S., et al. Cardiac rehabilitation in people with peripheral arterial disease: A higher risk population that benefits from completion. Int J Cardiol. 2019;285:108- 14. DOI:10.1002/14651858.CD000990.pub4.</mixed-citation><mixed-citation xml:lang="en">Devrome A.N., Aggarwal S., McMurtry M.S., et al. Cardiac rehabilitation in people with peripheral arterial disease: A higher risk population that benefits from completion. Int J Cardiol. 2019;285:108- 14. DOI:10.1002/14651858.CD000990.pub4.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hageman D., Fokkenrood H.J., Gommans L.N., et al. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev. 2018;4:CD005263. DOI:10.1002/14651858.CD005263.pub4.</mixed-citation><mixed-citation xml:lang="en">Hageman D., Fokkenrood H.J., Gommans L.N., et al. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev. 2018;4:CD005263. DOI:10.1002/14651858.CD005263.pub4.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">McDermott M.M., Spring B., Berger J.S., et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA. 2018;319(16):1665-76. DOI:10.1001/jama.2018.3275.</mixed-citation><mixed-citation xml:lang="en">McDermott M.M., Spring B., Berger J.S., et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA. 2018;319(16):1665-76. DOI:10.1001/jama.2018.3275.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Сумин А.Н., Косова М.А., Медведева Ю.А. и др. Факторы, влияющие на летальный исход, у пациентов с облитерирующими заболеваниями артерий нижних конечностей. Рациональная Фармакотерапия в Кардиологии. 2017;13(6):746-55. DOI:10.20996/1819-6446-2017-13-6-746-755</mixed-citation><mixed-citation xml:lang="en">Sumin A.N., Kosova M.A., Medvedeva J.D., et al. Factors Influencing on the Mortality in Patients with Obliterating Diseases of Lower Limb Arteries. Rational Pharmacotherapy in Cardiology 2017;13(6):746-55. DOI:10.20996/1819-6446-2017-13-6-746-755 (In Russ).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
